Abbott agrees to voluntarily withdraw obesity medication Meridia from U.

Related StoriesResearch abstracts on weight problems, weight loss to be shown at ObesityWeek 2015Standing one-quarter of the day linked to decreased likelihood of obesityTwo Duke weight problems experts' articles appear in the November issue of Health AffairsMeridia was approved by the FDA in November 1997 for weight loss and maintenance of pounds reduction in obese people, as well as in certain over weight people with other risks for heart disease. The approval was based on scientific data displaying that more folks receiving sibutramine dropped at least 5 % of their bodyweight than people on placebo who relied on exercise and diet only.John Rothman, Executive VP of Research and Operations said, ‘Prostate cancer is an excellent target for immunotherapy. We believe our approach compares favorably with the lately accepted Provenge treatment. Advaxis’ vaccine is simple and less expensive, since it is made up of three vaccinations, which strike all prostate cancer without the need to be patient specific.’ Advaxis’ prostate cancers vaccine generates a strong immunologic response that episodes and kills cells that secrete prostate specific antigen , a typically used scientific indicator of prostate cancer.